ReviewNature reviews. Disease primers2026
Necrotizing enterocolitis.
Review in Nature reviews. Disease primers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- PROTECT-Preterm: emulating target trials of dynamic probiotic strategies for necrotising enterocolitis, late-onset sepsis and mortality in very preterm infants - a study protocol.BMJ paediatrics open · 2026Article
- Integrated multi-omics analysis reveals dendritic cell centered regulatory networks and therapeutic targets in necrotizing enterocolitis.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Necrotizing enterocolitis (NEC) is a devastating condition that affects premature infants and remains one of the leading causes of death in neonatal intensive care units worldwide. Current approaches to the diagnosis and treatment of NEC have changed minimally in the past 30 years, in part due to an incomplete understanding of the biological mechanisms of the disease, and a lack of treatment options. Importantly however, recent research advances have improved our understanding of the pathogenesis of NEC, resulting in a broader approach to diagnosis, prevention and treatment. In parallel, an increased understanding of the long-term complications of NEC has shed light on the importance of early decision-making for patients with this disease. This Primer includes insights from an international team of clinician-investigators from Europe, Asia and North America, which now seeks to answer some of the key questions in the NEC field, with a focus on understanding epidemiology, pathogenesis and optimal management, including the fact that many infants with NEC require surgery, and to understand the morbidity that survivors experience. We also highlight how the future care of patients with NEC is likely to include a sophisticated diagnostic approach that includes novel molecular and imaging analyses, leading to the precise delivery of targeted molecular and cellular therapies, so as to improve outcomes in infants with this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.